JP2016028085A5 - - Google Patents

Download PDF

Info

Publication number
JP2016028085A5
JP2016028085A5 JP2015182821A JP2015182821A JP2016028085A5 JP 2016028085 A5 JP2016028085 A5 JP 2016028085A5 JP 2015182821 A JP2015182821 A JP 2015182821A JP 2015182821 A JP2015182821 A JP 2015182821A JP 2016028085 A5 JP2016028085 A5 JP 2016028085A5
Authority
JP
Japan
Prior art keywords
water
darunavir hydrate
crystalline
hydrate
darunavir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015182821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016028085A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016028085A publication Critical patent/JP2016028085A/ja
Publication of JP2016028085A5 publication Critical patent/JP2016028085A5/ja
Pending legal-status Critical Current

Links

JP2015182821A 2010-01-05 2015-09-16 ダルナビルの多形及びその製造方法 Pending JP2016028085A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN33MU2010 2010-01-05
IN33/MUM/2010 2010-01-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012546497A Division JP2013516397A (ja) 2010-01-05 2010-10-06 ダルナビルの多形及びその製造方法

Publications (2)

Publication Number Publication Date
JP2016028085A JP2016028085A (ja) 2016-02-25
JP2016028085A5 true JP2016028085A5 (enExample) 2016-04-07

Family

ID=43125640

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012546497A Pending JP2013516397A (ja) 2010-01-05 2010-10-06 ダルナビルの多形及びその製造方法
JP2015182821A Pending JP2016028085A (ja) 2010-01-05 2015-09-16 ダルナビルの多形及びその製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012546497A Pending JP2013516397A (ja) 2010-01-05 2010-10-06 ダルナビルの多形及びその製造方法

Country Status (9)

Country Link
US (2) US20130029945A1 (enExample)
EP (1) EP2521728B1 (enExample)
JP (2) JP2013516397A (enExample)
KR (1) KR20120123077A (enExample)
AU (1) AU2010340799B2 (enExample)
CA (1) CA2785998A1 (enExample)
NZ (1) NZ600994A (enExample)
WO (1) WO2011083287A2 (enExample)
ZA (1) ZA201204365B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2767539B1 (en) 2002-05-16 2017-07-12 Janssen Sciences Ireland UC Pseudopolymorphic forms of a HIV protease inhibitor
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
CN102725295A (zh) 2010-01-28 2012-10-10 Mapi医药公司 制备达芦那韦和达芦那韦中间体的方法
US9216990B2 (en) * 2011-12-05 2015-12-22 Mylan Labs Limited Crystalline Darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
ES2969589T3 (es) 2012-07-24 2024-05-21 Laurus Labs Ltd Solvato de Propionato de Darunavir
WO2016092525A1 (en) 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
CN106854212A (zh) * 2015-12-08 2017-06-16 浙江九洲药业股份有限公司 一种达芦那韦无定型的制备方法
CN106242307A (zh) * 2016-08-11 2016-12-21 京东方科技集团股份有限公司 用于强化制品的边缘的方法、玻璃及显示装置
EP3532478B1 (en) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form of darunavir free base
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN108794498A (zh) * 2017-05-03 2018-11-13 江苏瑞科医药科技有限公司 一种达芦那韦无定型的制备方法
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7669794A (en) 1993-08-24 1995-03-21 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
ES2604662T3 (es) 1998-06-23 2017-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Ensayo de acondicionamiento físico y métodos para reducir la resistencia del VIH a la terapia
EP2767539B1 (en) 2002-05-16 2017-07-12 Janssen Sciences Ireland UC Pseudopolymorphic forms of a HIV protease inhibitor
HRP20090488T1 (hr) 2003-12-23 2009-10-31 Tibotec Pharmaceuticals Ltd. Postupak za pripravu (3r,3as,6ar)-heksahidrofuro[2,3-b]furan-3-il(1s,23)-3-[[(4-aminofenil)sulfonil](izobutil)amino]-1-benzil-2-hidroksipropilkarbamata
US8703980B2 (en) * 2009-09-17 2014-04-22 Siva Rama Prasad Vellanki Process for the preparation of darunavir
CN102686594A (zh) * 2009-12-16 2012-09-19 熙德隆研究基金会 地瑞那韦的多晶型物

Similar Documents

Publication Publication Date Title
JP2016028085A5 (enExample)
JP2018024682A5 (enExample)
RU2018101363A (ru) Кристаллическая форма свободного основания лорлатиниба
JP2013237682A5 (enExample)
JP2014169319A5 (enExample)
WO2014209841A3 (en) Compounds for treating spinal muscular atrophy
NZ600994A (en) Darunavir polymorph and process for preparation thereof
HRP20171151T1 (hr) Inhibitori cdc7
JP2014501766A5 (enExample)
RU2015103065A (ru) Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения
HRP20121028T1 (hr) Kristalni oblici febuksostata
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
JP2015500331A5 (enExample)
JP2013520424A5 (enExample)
JP2015528812A5 (enExample)
JP2016540749A5 (enExample)
RU2015156142A (ru) Бисульфат ингибитора янус-киназы (jak) и способ его получения
JP2008019161A5 (enExample)
ME02838B (me) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
TW201613931A (en) Form crystal of bisulfate of janus kinase (JAK) inhibitor and preparation method thereof
JP2020536893A5 (enExample)
CL2015002606A1 (es) Compuesto.
JP2015129106A5 (enExample)
RU2022109286A (ru) Кристаллическая форма гидрата свободного основания лорлатиниба
JP2015506987A5 (enExample)